BG105162A - Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions - Google Patents

Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Info

Publication number
BG105162A
BG105162A BG105162A BG10516201A BG105162A BG 105162 A BG105162 A BG 105162A BG 105162 A BG105162 A BG 105162A BG 10516201 A BG10516201 A BG 10516201A BG 105162 A BG105162 A BG 105162A
Authority
BG
Bulgaria
Prior art keywords
coadministration
acat
mmp inhibitors
treatment
atherosclerotic lesions
Prior art date
Application number
BG105162A
Other languages
Bulgarian (bg)
English (en)
Inventor
Thomas BOCAN
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of BG105162A publication Critical patent/BG105162A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
BG105162A 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions BG105162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21
PCT/US1999/013948 WO2000004892A2 (en) 1998-07-21 1999-06-18 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Publications (1)

Publication Number Publication Date
BG105162A true BG105162A (en) 2001-12-29

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105162A BG105162A (en) 1998-07-21 2001-01-17 Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions

Country Status (25)

Country Link
EP (1) EP1098662A2 (cs)
JP (1) JP2002521328A (cs)
KR (1) KR20010083134A (cs)
CN (1) CN1310629A (cs)
AP (1) AP2001002035A0 (cs)
AU (1) AU4701799A (cs)
BG (1) BG105162A (cs)
BR (1) BR9912296A (cs)
CA (1) CA2335062A1 (cs)
CZ (1) CZ2001126A3 (cs)
EA (1) EA200100153A1 (cs)
EE (1) EE200100046A (cs)
HR (1) HRP20010055A2 (cs)
HU (1) HUP0102880A3 (cs)
ID (1) ID30030A (cs)
IL (1) IL140982A0 (cs)
IS (1) IS5809A (cs)
NO (1) NO20010291D0 (cs)
OA (1) OA11584A (cs)
PL (1) PL346011A1 (cs)
SK (1) SK502001A3 (cs)
TR (1) TR200100205T2 (cs)
WO (1) WO2000004892A2 (cs)
YU (1) YU3501A (cs)
ZA (1) ZA200100294B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
NZ524406A (en) * 2000-09-01 2004-06-25 Sankyo Co Medicinal compositions containing HMG-CoA reductase inhibitor and ACAT inhibitor
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
BR0308908A (pt) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
CA2492035A1 (en) * 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
DE69707865T2 (de) * 1996-05-17 2002-05-02 Warner-Lambert Co., Morris Plains Biphenylsulfonamid matrix metalloproteinase inhibitoren
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos

Also Published As

Publication number Publication date
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
JP2002521328A (ja) 2002-07-16
CZ2001126A3 (cs) 2002-01-16
HUP0102880A2 (en) 2002-06-29
KR20010083134A (ko) 2001-08-31
ID30030A (id) 2001-11-01
ZA200100294B (en) 2002-01-10
HRP20010055A2 (en) 2002-04-30
EA200100153A1 (ru) 2001-08-27
IL140982A0 (en) 2002-02-10
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
WO2000004892A2 (en) 2000-02-03
PL346011A1 (en) 2002-01-14
NO20010291L (no) 2001-01-18
WO2000004892A3 (en) 2000-05-18
EP1098662A2 (en) 2001-05-16
CN1310629A (zh) 2001-08-29
HUP0102880A3 (en) 2002-11-28
SK502001A3 (en) 2002-06-04
TR200100205T2 (tr) 2001-05-21
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (no) 2001-01-18
BR9912296A (pt) 2001-04-17
YU3501A (sh) 2005-06-10
EE200100046A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
BG105162A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
EP1935423A3 (de) Zusammensetzung zur Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
MY129409A (en) Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
IL128080A0 (en) Thiol sulfonamide metalloprotease inhibitors
IL141957A0 (en) 5ht1 receptor agonists and metoclopramide for the treatment of migraine
AU3103099A (en) Microbubble-based ultrasonic contrast agents for pressure measurements
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
AU3124300A (en) Inhibitors of beta-lactamases and uses therefor
ZA991744B (en) Combination of a selective NMDA NR2B antagonist and COX-2 inhibitor.
FR2744621B1 (fr) Determination des tunnels femoral et tibial pour la reconstruction isometrique du ligament croise anterieur
EP1101420A4 (en) STAMP PROVIDING A STABLE CROWD DURING THE RACE AND RUNNING SHOES
WO1999002565A3 (de) Mittel zur behandlung und/oder prophylaxe von mikrozirkulationsstörungen
EP0755679A3 (en) Use of Amtolmetin Guacil as an anti-inflammatory agent, which also inhibits gastric secretion
CA2322967A1 (en) Prophylactic, therapeutic agent for osteoporosis
WO1999043308A3 (en) Treating pulmonary hypertension through tenascin suppression and elastase inhibition
GB9824875D0 (en) Use of an agent for the prevention of gum disease
IL152989A0 (en) Use of riluzole or its salts for preventing and treating ?noleukodystrophy
MD1167F1 (en) Apparatus for anastomosis formation
EP1115687A4 (en) 5,6-DIHYDRONAPHTHALENYL DERIVATIVES WITH RETINOID-LIKE ACTIVITY
HUP9903964A3 (en) Methods and compositions for preventing or retarding the development of atherosclerotic lesions
AU7833298A (en) New human carboxypeptidase inhibitor
TW374520U (en) Increasing and deducting structure for the metal guide foot of the computer line terminals
HK1033310A (en) Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
KR960027392U (ko) 로터리 압축기의 마모감소장치